Literature DB >> 15643522

Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.

Hideaki Miyake1, Isao Hara, Kazuki Yamanaka, Mototsugu Muramaki, Martin Gleave, Hiroshi Eto.   

Abstract

Overexpression of insulin-like growth factor binding protein-2 (IGFBP-2) has been shown to be associated with tumor progression in several human malignant tumors; however, the significance of IGFBP-2 expression in bladder cancer remains poorly defined. The objective of this study was to investigate the effect of IGFBP-2 overexpression in human bladder cancer KoTCC-1 cells on their phenotype associated with tumor progression. We introduced IGFBP-2 cDNA into KoTCC-1 cells, which do not express a detectable level of IGFBP-2 protein, thus generating an IGFBP-2 overexpressing cell line (KoTCC-1/BP2). We also generated a vector-only-transfected cell line (KoTCC-1/C) as a control. Despite the absence of a significant difference in in vitro cell growth rates and motilities among KoTCC-1 sublines, KoTCC-1/BP2 exhibited significantly higher invasive ability than KoTCC-1/C. Gelatin zymography showed a marked increase in matrix metalloproteinase-2 (MMP-2) production by KoTCC-1/BP2 compared with that by KoTCC-1/C. Furthermore, there was no significant difference in sub-cutaneous tumor growth among KoTCC-1 sublines; however, more advanced tumor progression, including lymph node metastasis and hemorrhagic ascites formation, was observed after the implantation of KoTCC-1/BP2 into the bladder wall of nude mice than after the implantation of KoTCC-1/C. These findings suggest that overexpression of IGFBP-2 induces an increase in MMP-2 production, resulting in the enhanced metastatic potential of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643522

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.

Authors:  Toshiro Migita; Tadahito Narita; Reimi Asaka; Erika Miyagi; Hiroko Nagano; Kimie Nomura; Masaaki Matsuura; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Seimiya; Yuichi Ishikawa
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

3.  Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling.

Authors:  Adda Grimberg; Carrie M Coleman; Zonggao Shi; Timothy F Burns; Timothy K MacLachlan; Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2006-10-30       Impact factor: 4.742

4.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

5.  Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A.

Authors:  Zonggao Shi; Maria J Henwood; Peter Bannerman; Dalia Batista; Anelia Horvath; Marta Guttenberg; Constantine A Stratakis; Adda Grimberg
Journal:  Growth Horm IGF Res       Date:  2007-02-05       Impact factor: 2.372

Review 6.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

Review 7.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09

Review 8.  IGFBP2: integrative hub of developmental and oncogenic signaling network.

Authors:  Tao Li; M Elizabeth Forbes; Gregory N Fuller; Jiabo Li; Xuejun Yang; Wei Zhang
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

9.  The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis.

Authors:  Jiafeng Shou; Qi Zhang; Dahong Zhang
Journal:  World J Urol       Date:  2021-05-24       Impact factor: 4.226

10.  Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer.

Authors:  Ying Zhang; Xia Ying; Suxia Han; Jing Wang; Xia Zhou; E Bai; Jianying Zhang; Qing Zhu
Journal:  Int J Oncol       Date:  2012-11-15       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.